

Date	Presenter	Title	Journal	Year	Vol	Page
2021/12/7	古本	Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial	Lancet Oncol.	2021	22(10)	1378-1390
	加藤	Patient similarity network of newly diagnosed multiple myeloma identifies patient subgroups with distinct genetic features and clinical implications	Sci Adv	2021	7(47)	eabg9551
2021/12/14	勝岡	Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21)	Blood Adv	2021	5(10)	2481-2489
	今泉	Clinical significance of TP53 mutations in adult T-cell leukemia/lymphoma	Br J Haematol	2021	195(4)	571-584
2021/12/21	西村	Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma	N Engl J Med	2022	386(4)	351-363
	安東	The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance	Cancer Cell	2021	39(7)	999-1014
2021/12/28	坂本	Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma	N Engl J Med	2022	386(7)	640-654
	糸永	Lysine acetylation restricts mutant IDH2 activity to optimize transformation in AML cells	Mol Cell	2021	81(18)	3833-3847
2022/1/4	藤岡	Clinical evolution, genetic landscape and trajectories of clonal hematopoiesis in SAMD9/SAMD9L syndromes	Nat Med	2021	27(10)	1806-1817
	佐藤	A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs	Blood	2021	138 (21)	2031-2041
2022/1/11	山田	Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia	Blood Adv	2021	5(24)	5565-5573
	宮崎	BCOR gene alterations in hematologic diseases	Blood	2021	138(24)	2455-2468
2022/1/18	クリクラ学生	Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma	J Clin Oncol	2021	39(20)	2257-2265
	長井	Relationship between clone metrics and clinical outcome in clonal cytopenia	Blood	2021	138(11)	965-976
2022/2/8	渡辺	Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia	N Engl J Med	2022	386(1)	11-23
	澤山	Outcome of Allogeneic Hematopoietic Cell Transplantation after Venetoclax and Hypomethylating Agent Therapy for Acute Myelogenous Leukemia	Biol Blood Marrow Transplant	2020	26(12)	e322-e327
2022/2/15	クリクラ学生	Sequential CD19/22 CAR T-cell immunotherapy following autologous stem cell transplantation for central nervous system lymphoma	Blood Cancer J	2021	11(7)	131
	加藤	Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy	J Clin Oncol	2022	40(4)	369-381
2022/2/22	西村	第12回日本血液学会九州地方会 予行				
	今泉	2021年度JOCG リンパ腫班会議 報告				
2022/3/1	古本	Human Cytomegalovirus-Specific T-Cell Reconstitution and Late-Onset Cytomegalovirus Infection in Hematopoietic Stem Cell Transplantation Recipients following Letermovir Prophylaxis	Transplant Cell Ther	2022		S2666-6367(22)00028-8
	安東	Acute myeloid leukemia maturation lineage influences residual disease and relapse following differentiation therapy	Nat Commun	2021	12(1)	6546
2022/3/8	坂本	Naive T-Cell Depletion to Prevent Chronic Graft-Versus-Host Disease	J Clin Oncol	2022		JCO2101755
	佐藤	Cardiovascular disease is a leading cause of mortality among TTP survivors in clinical remission	Blood Adv	2022	6(4)	1264-1270
2022/3/15	藤岡	Indeterminate and oncogenic potential: CHIP vs CHOP mutations in AML with NPM1 alteration	Leukemia	2022	36(2)	394-402
	長井	Risk profiling of patients with relapsed/refractory diffuse large B-cell lymphoma by measuring circulating tumor DNA	Blood Advances	2022	6(6)	1651-1660
2022/3/22	勝岡	第44回日本造血・免疫細胞療法学会 予行				
	渡辺					
2022/3/29	山田	第44回日本造血・免疫細胞療法学会 予行				
	糸永					